Minter Larry J, Clarke Elsburgh O, Gjeltema Jenessa L, Archibald Kate E, Posner Lysa P, Lewbart Gregory A
Department of Clinical Sciences, North Carolina State University, College of Veterinary Medicine, 4700 Hillsborough Street, Raleigh, North Carolina 27606, USA.
J Zoo Wildl Med. 2011 Dec;42(4):680-5. doi: 10.1638/2011-0126.1.
Meloxicam is a commonly used nonsteroidal anti-inflammatory drug (NSAID) in veterinary medicine, but its use in amphibians has not been reported in the literature. NSAIDs are known to act by providing anti-inflammatory and analgesic actions by inhibiting the synthesis of prostaglandin E2 (PGE2). The objective of this study was to evaluate whether the intramuscular administration of meloxicam would decrease the circulating serum PGE2 levels in the North American bullfrog (Rana catesbeiana) following tissue trauma induced by a punch biopsy. Eighteen adult North American bullfrogs were randomly assigned to two treatment groups: meloxicam (0.1 mg/kg i.m.) and control (0.9% saline i.m.). Blood was obtained via cardiocentesis immediately prior to administration of the two treatment regimes and serum was frozen. A 4-mm punch biopsy was taken from the right triceps femoris muscle to induce an inflammatory response. Twenty-four hours later, a second blood sample was collected and serum was harvested and frozen. Serum PGE2 concentrations were measured using a commercial PGE2 enzyme assay (EIA) kit. Twenty-four hours following the biopsy, the mean circulating PGE2 levels of animals treated with meloxicam was 57.79 +/- 12.35 pg/ml, which did not differ significantly from animals that were treated with saline (85.63 +/- 17.55 pg/ml, P > or = 0.05). The calculated means of the absolute change between the circulating baseline PGE2 levels and the postinjury circulating PGE2 levels were significantly lower in animals treated with meloxicam (13.11 +/- 17.31 pg/ml) than in control animals treated with saline (46.14 +/- 38.02 pg/ml) (P < or = 0.05). These results suggest that the systemic administration of meloxicam at a dosage of 0.1 mg/kg once daily suppresses circulating serum PGE2 levels postinjury in the North American bullfrog.
美洛昔康是兽医学中常用的非甾体抗炎药（NSAID），但两栖动物使用美洛昔康的情况在文献中尚无报道。已知NSAID通过抑制前列腺素E2（PGE2）的合成发挥抗炎和镇痛作用。本研究的目的是评估肌肉注射美洛昔康是否会降低北美牛蛙（Rana catesbeiana）在穿孔活检诱导组织损伤后的循环血清PGE2水平。18只成年北美牛蛙被随机分为两个治疗组：美洛昔康组（0.1mg/kg肌肉注射）和对照组（0.9%生理盐水肌肉注射）。在给予两种治疗方案之前，立即通过心脏穿刺采血并将血清冷冻。从右股三头肌取4mm的穿孔活检以诱导炎症反应。24小时后，采集第二份血样并收获血清并冷冻。使用商用PGE2酶联免疫吸附测定（EIA）试剂盒测量血清PGE2浓度。活检后24小时，接受美洛昔康治疗的动物的平均循环PGE2水平为57.79±12.35pg/ml，与接受生理盐水治疗的动物（85.63±17.55pg/ml，P≥0.05）无显著差异。美洛昔康治疗的动物循环基线PGE2水平与损伤后循环PGE2水平之间的绝对变化计算平均值（13.11±17.31pg/ml）显著低于生理盐水治疗的对照动物（46.14±38.02pg/ml）（P≤0.05）。这些结果表明，北美牛蛙每天一次以0.1mg/kg的剂量全身给药美洛昔康可抑制损伤后循环血清PGE2水平。
